JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2001; 38:1829-1835
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verdecchia, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verdecchia, P.

CLINICAL STUDY: RISK FACTORS

Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study

Paolo Verdecchia, MD, FACC*,a, Giancarlo Carini, MDa, Antonio Circo, MDa, Emilio Dovellini, MDa, Ezio Giovannini, MDa, Michele Lombardo, MDa, Pasquale Solinas, MDa, Marco Gorini, MDa, Aldo Pietro Maggioni, MDa the MAVI Study Group

a ANMCO Research Center, Via La Marmora, 36 Firenze, Italy. Please see for MAVI Study Group participants

Manuscript received December 30, 2000; revised manuscript received August 14, 2001, accepted August 29, 2001.

* Reprint requests and correspondence: Dr. Paolo Verdecchia, ANMCO Research Center, Via La Marmora, 39, 50121-Firenze, Italy
verdec{at}tin.it

OBJECTIVES

This study investigated the prognostic value of left ventricular (LV) mass at echocardiography in uncomplicated subjects with essential hypertension.

BACKGROUND

Only a few single-center studies support the prognostic value of LV mass in uncomplicated hypertension.

METHODS

The MAssa Ventricolare sinistra nell’Ipertensione study was a multicenter (45 centers) prospective study. The prespecified aim was to explore the prognostic value of LV mass in hypertension. Admission criteria included essential hypertension, no previous cardiovascular events, and age ≥50. There was central reading of echocardiographic tracings. Treatment was tailored to the single subject.

RESULTS

Overall, 1,033 subjects (396 men) were followed for 0 to 4 years (median, 3 years). Mean age at entry was 60 years, and systolic/diastolic blood pressure was 154/92 mm Hg. The rate of cardiovascular events (x100 patient-years) was 1.3 in the group with normal LV mass and 3.2 in the group (28.5% of total sample) with LV mass ≥125 g/body surface area (p = 0.005). After adjustment for age (p < 0.01), diabetes (p < 0.01), cigarette smoking (p < 0.01) and serum creatinine (p = 0.03), LV hypertrophy was associated with an increased risk of events (RR [relative risk] 2.08; 95% CI [confidence interval]: 1.22 to 3.57). For each 39 g/m2 (1 SD) increase in LV mass there was an independent 40% rise in the risk of major cardiovascular events (95% CI: 14 to 72; p = 0.0013).

CONCLUSIONS

Our findings show a strong, continuous and independent relationship of LV mass to subsequent cardiovascular morbidity. This is the first study to extend such demonstration to a large nationwide multicenter sample of uncomplicated subjects with essential hypertension.

Abbreviations and Acronyms
  ANMCO = Associazione Nazionale Medici Cardiologi Ospedalieri
  BP = blood pressure
  BSA = body surface area
  ECG = electrocardiography
  LV = left ventricular
  MAVI = Massa Ventricolare Sinistra nell’Ipertensione
  MI = myocardial infarction




This article has been cited by other articles:


Home page
NEJMHome page
J. A. Hill and E. N. Olson
Cardiac Plasticity
N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
K. Taniguchi, T. Takahashi, K. Toda, H. Matsue, Y. Shudo, H. Shintani, M. Mitsuno, and Y. Sawa
Left ventricular mass: impact on left ventricular contractile function and its reversibility in patients undergoing aortic valve replacement
Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 588 - 595.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. K. Mehta, J. E. Rame, A. Khera, S. A. Murphy, R. M. Canham, R. M. Peshock, J. A. de Lemos, and M. H. Drazner
Left Ventricular Hypertrophy, Subclinical Atherosclerosis, and Inflammation
Hypertension, June 1, 2007; 49(6): 1385 - 1391.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. F. Elias, L. M. Sullivan, P. K. Elias, R. B. D'Agostino Sr, P. A. Wolf, S. Seshadri, R. Au, E. J. Benjamin, and R. S. Vasan
Left Ventricular Mass, Blood Pressure, and Lowered Cognitive Performance in the Framingham Offspring
Hypertension, March 1, 2007; 49(3): 439 - 445.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. R. Heckbert, W. Post, G. D.N. Pearson, D. K. Arnett, A. S. Gomes, M. Jerosch-Herold, W. G. Hundley, J. A. Lima, and D. A. Bluemke
Traditional Cardiovascular Risk Factors in Relation to Left Ventricular Mass, Volume, and Systolic Function by Cardiac Magnetic Resonance Imaging: The Multiethnic Study of Atherosclerosis
J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2285 - 2292.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Schalla, C. B. Higgins, M. Chujo, and M. Saeed
Effect of Potassium-Channel Opener Therapy on Reperfused Infarction in Hypertrophied Hearts: Demonstration of Preconditioning by Using Functional and Contrast-Enhanced Magnetic Resonance Imaging
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 193 - 202.
[Abstract] [PDF]


Home page
HypertensionHome page
M. P. Schneider, A. U. Klingbeil, C. Delles, M. Ludwig, R. E. Kolloch, M. Krekler, K. O. Stumpe, and R. E. Schmieder
Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage: Results of the CardioVascular Irbesartan Project
Hypertension, July 1, 2004; 44(1): 61 - 66.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Pacifico and P. D. Henry
Ablation for atrial fibrillation: are cures really achieved?
J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1940 - 1942.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
H. Ogita, K. Node, Y. Liao, F. Ishikura, S. Beppu, H. Asanuma, S. Sanada, S. Takashima, T. Minamino, M. Hori, et al.
Raloxifene Prevents Cardiac Hypertrophy and Dysfunction in Pressure-Overloaded Mice
Hypertension, February 1, 2004; 43(2): 237 - 242.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. G Friedrich, B. Dahlof, U. Sechtem, T. Unger, M. Knecht, R. Dietz, and TELMAR Investigators
Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension -- a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months -- rationale and study design
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2003; 4(4): 234 - 243.
[Abstract] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. de Simone
Left Ventricular Geometry and Hypotension in End-Stage Renal Disease: A Mechanical Perspective
J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2421 - 2427.
[Abstract] [Full Text] [PDF]


Home page
Eur J EchocardiogrHome page
A.D McGavigan, F.G Dunn, and N.E.R Goodfield
Secondary harmonic imaging overestimates left ventricular mass compared to fundamental echocardiography
Eur J Echocardiogr, September 1, 2003; 4(3): 178 - 181.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G. P. Bezante, G. Deferrari, et al.
Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension
Hypertension, July 1, 2003; 42(1): 14 - 18.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Zhang, D. Carreras, and A. J. de Bold
Discoordinate re-expression of cardiac fetal genes in N{omega}-nitro-L-arginine methyl ester (L-NAME) hypertension
Cardiovasc Res, January 1, 2003; 57(1): 158 - 167.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. de Simone, P. Verdecchia, S. Pede, M. Gorini, and A. P. Maggioni
Prognosis of Inappropriate Left Ventricular Mass in Hypertension: The MAVI Study
Hypertension, October 1, 2002; 40(4): 470 - 476.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2001 by the American College of Cardiology Foundation.